Antiretroviral treatment (ART) for women living with HIV is vital to ensuring safe motherhood and reducing vertical transmission. Each year, as many as 42,000 women living with HIV die of HIV and pregnancy-related complications. While significant progress has been made with 93% of pregnant women in 22 priority countries who have accessed combination ART (or cART, formerly called HAART), not all pregnant women can access treatment. In low- and middle-income countries in particular, treatment access for pregnant women living with HIV has been hampered by availability of medications and standardized treatment eligibility criteria that traditionally prioritized prevention of HIV transmission to the infant over treatment for the health of the woman. This brief summarizes the issues, interventions, and evidence as of 2016.
Gay, Jill, Melanie Croce-Galis, Karen Hardee, and Mackenzie Kacmarcik. 2016. “Antiretroviral treatment for pregnant women living with HIV: A summary of issues, interventions, and evidence.” Washington, DC: Population Council, The Evidence Project and What Works Association.
The Evidence Project